Last update 27 Feb 2026

Mesenchymal Stem Cells(Car-T (Shanghai) Biotechnology)

Overview

Basic Info

Drug Type
Mesenchymal stem cell therapy
Synonyms-
Target-
Action-
Mechanism
Cell replacements
Therapeutic Areas
Immune System DiseasesDigestive System DisordersEndocrinology and Metabolic Disease+ [1]
Active Indication-
Inactive Indication
Decompensated cirrhosis of liverDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2+ [2]
Originator Organization
CAR T (Shanghai) Biotech Co., Ltd.CAR T (Shanghai) Biotech Co., Ltd.
Active Organization-
Inactive Organization
Changhai Hospital of Shanghai
License Organization-
Drug Highest PhasePendingEarly Phase 1
First Approval Date-
Regulation-
Login to view timeline

Related

6
Clinical Trials associated with Mesenchymal Stem Cells(Car-T (Shanghai) Biotechnology)
NCT05127369
/ Not yet recruitingNot Applicable
Safety and Efficacy of Dental Pulp Mesenchymal Cells in the Treatment of Depression:
NCT04302519
/ Unknown statusEarly Phase 1
Clinical Study of Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells
NCT03957655
/ Unknown statusEarly Phase 1IIT
Safety and Efficacy of Stem Cells From Human Exfoliated Deciduous Teeth for Treatment of Decompensated Liver Cirrhosis
100 Clinical Results associated with Mesenchymal Stem Cells(Car-T (Shanghai) Biotechnology)
Login to view more data
100 Translational Medicine associated with Mesenchymal Stem Cells(Car-T (Shanghai) Biotechnology)
Login to view more data
100 Patents (Medical) associated with Mesenchymal Stem Cells(Car-T (Shanghai) Biotechnology)
Login to view more data
100 Deals associated with Mesenchymal Stem Cells(Car-T (Shanghai) Biotechnology)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Decompensated cirrhosis of liverPhase 1
China
-02 Dec 2019
FibrosisPhase 1
China
Changhai Hospital of Shanghai
02 Dec 2019
Liver CirrhosisPhase 1
China
Changhai Hospital of Shanghai
02 Dec 2019
Diabetes Mellitus, Type 1Phase 1
China
-05 Jan 2019
Diabetes Mellitus, Type 2Phase 1
China
-01 Jun 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free